Cresco Labs Wins Its Shareholder Vote to Chase a Big-Board Listing — But Can a $0.64 Stock Clear the Bar?

Shares edged up +1.0% to $0.64 as Cresco Labs, one of America's largest cannabis operators, announced that shareholders overwhelmingly approved a corporate overhaul designed to pave the way for a listing on a major U.S. stock exchange like the NYSE or Nasdaq. The question now: does the plumbing work matter if the stock price doesn't cooperate?

Shareholders Gave Near-Unanimous Backing, but the Hard Part Is Ahead. At its October 30 meeting, voters approved three resolutions — creating a new parent company, authorizing a move from British Columbia to Delaware, and extending the sunset on special voting shares — each with at least 94% support.

The board has until December 31, 2027 to execute the Delaware move. The restructuring is necessary scaffolding, but it is not a listing itself — it merely removes legal roadblocks.

A $4 Share Price Is the Gatekeeper. Both Nasdaq and the NYSE require a minimum share price of $4.00 at the time of initial listing. At $0.64, Cresco trades more than 80% below that threshold. The board secured the right to do a reverse stock split — combining shares to boost the per-share price — but disclosed no ratio or timing. Rivals Trulieve and Glass House already used this playbook: both uplisted to the NYSE earlier this year after separating their medical cannabis businesses from their recreational operations — a structural step Cresco has not yet publicly detailed.

The Business Is Improving, but the Market Isn't Buying It. In Q2 2026, Cresco posted $173 million in revenue, $87 million in gross profit, and an adjusted gross margin of 51.6%.

Net income was $15 million , a notable swing from a $17 million loss in Q1. Yet the stock has cratered roughly 72% from its 52-week high of $2.30, and trailing twelve-month revenue of $651 million supports a market cap of only about $220 million — a fraction of one times sales.

Q3 Results on November 6 Will Test Momentum. Management guided for Q3 revenue roughly flat with Q2 and EBITDA margins compressing to about 20% , suggesting limited near-term acceleration. Investors will watch that print for evidence the uplisting thesis is more than hope. Until Cresco executes the medical-business separation, secures DEA registration, and engineers a share price above $4, the approved restructuring is a necessary but not sufficient step toward the big leagues.